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Worcester EM, Evan AP, Coe FL, Lingeman JE, Krambeck A,
Sommers A, Phillips CL, Milliner D. A test of the hypothesis that oxalate
secretion produces proximal tubule crystallization in primary hyperoxaluria
type I. Am J Physiol Renal Physiol 305: F1574–F1584, 2013. First published
October 2, 2013; doi:10.1152/ajprenal.00382.2013.—The sequence of
events by which primary hyperoxaluria type 1 (PH1) causes renal
failure is unclear. We hypothesize that proximal tubule (PT) is
vulnerable because oxalate secretion raises calcium oxalate (CaOx)
supersaturation (SS) there, leading to crystal formation and cellular
injury. We studied cortical and papillary biopsies from two PH1
patients with preserved renal function, and seven native kidneys
removed from four patients at the time of transplant, after short-term
(2) or longer term (2) dialysis. In these patients, and another five PH1
patients without renal failure, we calculated oxalate secretion, and
estimated PT CaOx SS. Plasma oxalate was elevated in all PH1
patients and inverse to creatinine clearance. Renal secretion of oxalate
was present in all PH1 but rare in controls. PT CaOx SS was 1 in
all nonpyridoxine-responsive PH1 before transplant and most marked
in patients who developed end stage renal disease (ESRD). PT from
PH1 with preserved renal function had birefringent crystals, confirm-
ing the presence of CaOx SS, but had no evidence of cortical
inflammation or scarring by histopathology or hyaluronan staining.
PH1 with short ESRD showed CaOx deposition and hyaluronan
staining particularly at the corticomedullary junction in distal PT
while cortical collecting ducts were spared. Longer ESRD showed
widespread cortical CaOx, and in both groups papillary tissue had
marked intratubular CaOx deposits and fibrosis. CaOx SS in PT
causes CaOx crystal formation, and CaOx deposition in distal PT
appears to be associated with ESRD. Minimizing PT CaOx SS may be
important for preserving renal function in PH1.
primary hyperoxaluria; calcium oxalate; renal histopathology; proxi-
mal tubule
AMPLE EVIDENCE SUGGESTS THAT calcium oxalate (CaOx) crystals
may injure proximal tubule (PT) cells (8, 43, 52) and could
potentially lead to cortical injury and renal failure in animals
(28–29) and humans (9, 24). However, whether or not formation
of CaOx crystals in the renal cortex is an initiating event in the
renal damage seen in human primary hyperoxaluria type 1 (PH1)
is unclear. Kidneys from PH1 patients with end stage renal disease
(ESRD) contain more cortical CaOx crystals than are found in
other ESRD patients (39), but this could reflect the higher plasma
oxalate concentrations present in PH1 patients with renal failure
(24): the abundant crystals could be secondary to renal failure in
PH1. Alternatively, high oxalate production and excretion in PH1
may cause PT crystals as a primary event, possibly even when
renal function is near normal. For example, oxalate loading of
animals produces cortical CaOx crystallizations in PT, especially
the S3 segment (30, 31), as an early event. Despite this body of
data, the exact sequence of events that produce ESRD in humans
with PH1 remains unclear.
To further the problem, we propose the hypothesis that high
oxalate entry into PT from filtration and secretion creates PT
CaOx supersaturation (SS) that leads to CaOx crystal forma-
tion, even when renal function is normal, causing kidney injury
and renal failure. One test of our hypothesis is to determine if
PT CaOx SS is plausible in PH1 patients. A second test is to
ask if CaOx crystals can be demonstrated in PT of PH1 patients
whose renal function is still near normal and whose cortical
cells are undamaged. Finally, because water extraction is most
complete in the S3 segment of the PT, we should be able to
demonstrate preferential CaOx accumulation at that site.
To perform the three needed tests, we have studied seven
kidneys from four PH1 patients with ESRD, as well as both
papillary and cortical biopsies from two PH1 patients who had
near normal renal function and were studied during percutane-
ous nephrolithotomy (PNL). One of the two was studied on
two occasions. Two more PH1 patients underwent intraopera-
tive imaging during PNL without biopsy, one of whom had
pyridoxine-sensitive PH1. Blood and urine studies were avail-
able on all eight patients.
With the use of these eight patients, and three additional
PH1 cases from whom we did not obtain renal tissue or in-
traoperative imaging but did obtain plasma and urine oxalate
on multiple occasions, we have been able to perform all three
tests of our hypothesis. Our observations during the course of
this work also allow us to present the surgical anatomy and
histopathology of early PH1, not hitherto described.
METHODS
Subjects
We have studied renal tissue and/or intraoperative images from
eight patients, and blood and urine oxalate levels from these patients
as well as three more patients from whom we did not obtain tissue or
images. All 11 had genetically proven PH1, but there were no 2
patients with the same genotype. Kidneys from patients 1, 2, 4, and 5
(Table 1) were obtained by native nephrectomy at the time of renal
transplantation. Patients 6 and 7 underwent intraoperative imaging
and papillary and cortical biopsy during PNL. Patient 7 had ureter-
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oscopy with mapping (no biopsy) and then a PNL procedure with
biopsy 2 yr later; this permitted mapping twice. The patient subse-
quently went on to ESRD over the next 12 mo. Patients 3 and 11 had
only intraoperative imaging via PNL. Patient 11 became dialysis
dependent 38 days postprocedure (PNL). At the time of PNL renal
function was well preserved in all four patients; creatinine clearance
values (ml·min1·1.73 M2) were as follows: 93  8, 74  6, 123 
16, and 70  7 for patients 3, 6, 7, and 11, respectively. All eight
patients with renal tissue and/or imaging, except patient 2, formed
pure CaOx stones; patient 2 was an infant who formed no stones
(Table 1). Patients 8-10 provided only blood and urine measurements.
The work was Institutional Review Board approved at both Mayo
Clinic (no. 11–001702, 11–005413, and 07–008751) and Indiana
University (no. 98–073). Patients are numbered in order of accession.
Clinical Laboratory Studies
Twenty-four hour urine samples and corresponding blood samples
were collected for clinical management at Mayo Clinic while patients
were eating their free choice diet. Because patients contributed vari-
able numbers of samples over time periods ranging from 1 to 19 yr
(median  5 and mean  6.6), and encompassing periods pre- and
posttransplant, the individual contributions of each patient to our
plasma and urine samples (numbers and timing of samples) are
documented in Table 2. A total of 98 measurements of plasma and/or
urine oxalate were collected over the course of treatment, including
periods before onset of ESRD and after kidney-liver transplant in 4
patients. Of the 98 measurements, 61 instances had plasma and urine
oxalate and creatinine obtained at the same time, allowing calculation
of oxalate secretion and 82 had urine oxalate measurement with serum
and urine creatinine, allowing calculation of PT CaOx SS (Table 3).
Each patient had at least one such measurement, although in two cases
the necessary information was only available after transplant. Twenty-
four-hour urines were collected for clinical management in patient 3
before and during treatment with pyridoxine. Urine oxalate was
greatly elevated in all cases (Table 3) except for the one pyridoxine-
responsive patient. Laboratory methods are detailed in prior publica-
tions (13, 17, 36, 58).
Because children and adults are analyzed together, we have ex-
pressed creatinine clearance, urine oxalate excretion, and urine vol-
ume per 1.73 M2 (Table 3). Values are means  SE for creatinine
clearances (in ml·min1·1.73 M2). In those patients who underwent
renal transplant, data are reported separately for the pre- and post-
transplant periods. In three patients who eventually developed ESRD
(patients 1, 5, and 7), laboratory data spanned periods in which renal
function changed markedly. In these patients, the median creatinine
clearance (CCr) was determined for the available data, and laborato-
ries reported separately for periods in which CCr was above (H) or
at-or-below (L) the median value.
Biopsy Protocol and Plaque Area Determination
During PNL all accessible papillae in patients 3, 6, 7, and 11 were
digitally imaged as described elsewhere for determination of plaque
area (17, 32). Biopsies were taken from the upper pole, interpolar, and
lower pole papillae and cortex in patients 6 and 7. Both kidneys from
patients 1 and 2 were studied via ex vivo ureteroscopy to mimic the
intraoperative mapping studies.
Tissue Analysis
General. Eight papillary and four cortical biopsies from patients 6
and 7, along with papillary and cortical samples from all four
nephrectomy cases, were studied using light microscopy. All speci-
mens were immersed in 5% paraformaldehyde in 0.1 mol/l phosphate
buffer pH 7.4 (PPB).
Light microscopy. Papillary and cortical specimens fixed in PPB
were dehydrated through a series of graded ethanol concentrations to
Table 1. Clinical characteristics of patients who had surgery
Stone Treatments
Pt Sex
Age at First
Stone, yr
Age at Dx
of PH1, yr Stones (#) ESWL URS
Surgery
type (#)
Presenting
Symptom
Age at
ESRD, yr
Time on
Dialysis, mo
Age at Time of
Procedure, yr Type of Procedure
1 M 37 47 20 4 1  Stone 56 2 56 LKT, bilat native Nx
2 F  1     Failure to thrive,
CKD
1 15 2 LKT, bilat native Nx
3 M 4 4 10  3 PNL (4) Stone   23 PNL
4 F 25 46 20/10 10/1  L Nx/Tx Nx Stone 43/46 24/19 48 LKT, native R Nx
5 M 2 3 10 4 4  Stone 19 9 20 LKT, bilat native Nx
6 F 2 2 7   NL, PNL (1) Stone   37 PNL, Bx
7 M 3 3 14 3 4 PNL (2) Stone 24  21 URS
23 PNL, Bx
11 M 15 24 20 1  PNL (2)
Open (4)
Stone 67 5 66 PNL
Pt, patient; M, male; F, female; Dx, diagnosis; PH1, primary hyperoxaluria type 1; ESWL, extracorporeal shock wave lithotripsy; URS, ureteroscopy; PNL,
percutaneous nephrolithotomy; Nx, nephrectomy; Tx, transplant; NL, nephrolithotomy; CKD, chronic kidney disease; ESRD, end stage renal disease; LKT, liver
and kidney transplant; Bx, papillary biopsy.
Table 2. Counts of serum and urine samples for oxalate SS and secretion by subject
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8 Pt 9 Pt 10 Pt 11 All
Age span 48–57 1–3 4–22 47–49 13–20 37–9 5–24 4–9 13–19 57–59 66
Pre-ESRD 10, 8, 8 2, 0, 0 15, 15, 11 3, 0, 0 11, 7, 1 4, 4, 1 13, 10, 5 11, 10, 9 15, 15, 14 4, 4, 4 2, 2, 2 90, 75, 55
Post-Tx 2, 2, 2 2, 1, 1 3, 3, 2 1,1,1 8, 7, 6
Total 12, 10, 10 4, 1, 1 15, 15, 11 6, 3, 2 12, 8, 2 4, 4, 1 13, 10, 5 11, 10, 9 15, 15, 14 4, 4, 4 2, 2, 2 98, 82, 61
Counts are total number of samples reporting 1) either serum or urine oxalate, 2) urine oxalate molarity with both serum and urine creatinine molarities (for
calculation of proximal tubule supersaturation (SS), and 3) serum and urine oxalate and creatinine molarities for calculation of oxalate secretion. Age spans are
from first to last set of measurements (yr). Pre-ESRD, measurements obtained before end stage renal disease with dialysis; Post-Tx, measurements obtained after
liver kidney transplant.
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100% ethanol before embedment in a 50/50 mixture of Paraplast Xtra
(Fisher) and Peel-away Micro-Cut (Polysciences). Twelve serial sec-
tions from each specimen were cut at 4 m and stained with the Yasue
metal substitution method for calcium histochemistry (16). Hematoxa-
lin and eosin for routine histological examination, Jones= silver stain
for the semiquantitation of glomerulosclerosis, and the Masson
Trichrome stain to determine sites of interstitial fibrosis at the light
microscopic level (Table 4). An additional set of serial sections was
cut at 7 m for infrared analysis. Because of the large amount of
mineral in some of the kidney samples and the high degree of tissue
injury, we used conjugated peanut agglutinin lectin (Arachis hypo-
gaea) to specifically stain distal tubules and lotus lectin (Lotus
tetragonolobus) for proximal tubules (23, 51). Medullary collecting
ducts were easily identified by their branching patterns while the
peanut agglutinin and lotus lectins permitted identification of cortical
collecting ducts by exclusion. Tissues were viewed using fluorescence
microscopy to visualize lectin staining.
In a double blind design, a renal pathologist (C. Phillips)
performed a semiquantitative analysis (18) using the Jones’ silver
stained or periodic acid Schiff-stained cortical sections from all
patients from whom tissue was available. Tubular atrophy and
interstitial fibrosis were independently scored on a scale of 0 to 3
(0  none, 1  mild or 34% of sample, 2  moderate or 34–66%,
and 3  severe or 66%). Glomerulosclerosis was defined as in-
creased mesangial matrix with or without wrinkling, thickening,
and/or collapse of glomerular basement membranes. Sclerosis of
individual glomeruli was scored as segmental (25%  mild, 25–
75%  moderate), or global (75%  severe or total obsolescence).
The total number of glomeruli observed and the number of glomeruli
in each of the three categories of sclerosis were recorded.
Hyaluronan staining. Hyaluronan was localized using biotinylated
hyaluronan acid binding protein, in both routine formalin fixed tissue and
the 10% formalin in 70% ethanol and 5% glacial acetic acid biopsies of
the cortex and papilla from patients 1, 2, 4, 5, 6, and 7. Paraffin-sectioned
tissue (cut at 4 m) was mounted on glass slides and processed as
described in our previous publication (11). Controls were performed with
the elimination of the primary antibody and showed no staining.
Crystal deposits. INFRARED. Attenuated Total Internal Reflection
(ATR) Fourier Transform Infrared Microspectroscopy (FTIR) was used
as described elsewhere (16) to identify mineral types in crystal deposits.
MICROCOMPUTED TOMOGRAPHY. All papillary biopsies underwent
microcomputed tomography (CT) analysis with the SkyScan-1072
(Vluchtenburgstraat 3, B-2630 Aartselaar, Belgium) high-resolution
desk-top CT system allowing nondestructive mapping of the location
and size of the crystalline deposits within a biopsy specimen. This CT
system can generate a tissue window so that both the mineral deposit and
tissue organization are seen at the same time. For this protocol, biopsies
are quickly dipped in a 1:10 dilution of Hypaque (50%; Nycomed,
Princeton, NJ)/PBS and then coated with a thin layer of paraffin and
mounted in the center of a small chuck that is then locked into place in
the machine. The sample was positioned in the center of the beam, and
the system configuration was set at 35 kV, 209 A, 180° rotation, with
flatfield correction. Images were saved to CDs and reconstructed with
Cone-Reconstruction software by SkyScan. These images were then
reconstructed into 3D images with SkyScan’s CTAn CTVol software.
These images allowed us to properly orient each biopsy for future light
microscopic analysis. The 3D software was used to generate quantitative
measurements of deposit size (mm) and density (mm3).
Calculation of Oxalate Secretion and PT SS
Absolute oxalate secretion (Sox) is calculated by mass balance (Eq. 1):
Sox Uox V (g Pox) (1)
where U and P are urine and plasma oxalate concentrations, g is GFR
as estimated by creatinine clearance, V is urine flow rate in the same
units as g (ml·min1·1.73 M2), and g 	 Pox is oxalate filtered load
(oxalate is freely ultrafiltered; Ref. 60).
Inputs of oxalate into PT are filtration and secretion; urine oxalate
is assumed to equal the sum of filtered and net secreted oxalate
(secretion minus any subsequent PT reabsorption). A crucial assump-
tion is that oxalate is neither added to or removed from tubule fluid
beyond the PT S3 segment; this is probable since only the proximal
tubule is known to contain both apical (SLC26a6) and basolateral
(SLC26a1) oxalate transporters, as would be required for net secretion
or absorption of oxalate from tubule fluid (1). The fluid available to
dissolve the oxalate is g minus the fraction of g reabsorbed: g(1  r)
where r is the fraction of g reabsorbed. The term (1  r) falls along
the PT reaching a minimum in the last portion, S3:
PTox V Uox/g1 r (2)
where PTox is the molar concentration of oxalate in PT at the value
of r achieved in the S3 segment, and Uox is urine oxalate molarity;
Table 3. Selected laboratory values by subject
Subject Type N U OX, mmol/day P OX, uM/l CCR, ml/min FL OX, umol/h Ox Sec, umol/h SSOX
1 N Pre Tx (H) 4 2.4  0.3 9  3 83  4 44  11 57  6 3  0.5
1 N Pre Tx (L) 6 2.0  0.5 17  7 52  6 43  12 41  10 5  2
1 N Post Tx 2 0.4  0.02 2  1 57  3 6  2 10  1 0.7 0.01
2 N Pre Tx 2  109  25    
2 N Post Tx 2 2.8 6  2 33 16 99 8.7
3 PNL 15 0.7  0.1 3  1 93  8 19  4 6  5 1.1 0.4
4 N Pre Tx 3  107  19    
4 N Post Tx 3 1.6  0.4 18  1 33  8 28  10 26  11 4.9 0.04
5 N Pre Tx (H) 5 2.5  0.5 7  4 95  4 38  27 36  26 2.8 0.6
5 N Pre Tx (L) 3 2.3  0.2  78  6   3.1  0.4
5 N Post Tx 1 0.5 1.9 93 11 10 0.5
6 PNL 4 1.8  0.3 4 74  6 20 42 2.7 0.7
7 PNL (H) 5 2.1  0.4 12  1 159  10 110 24 29  32 1.4  0.3
7 PNL (L) 5 1.6  0.1 8  2 88  20 54 23 11  28 2.7 0.8
8 No surg 10 2.5  0.1 9  2 38  3 19  4 88  6 7.4 0.8
9 No surg 15 1.7  0.2 9  1 59  4 31  4 40  6 3.1 0.2
10 No surg 4 3.1  0.2 32  12 57 15 81 15 48  14 7  2
11 PNL 2 1.6  0.02 11  2 70  7 43  5 23  4 2.4 0.3
Values are means  SE; N, patient who underwent native nephrectomy; PNL, patient studied at time of PNL; No surg, patient contributing no surgical data;
Pre Tx, pretransplant; Post Tx, posttransplant; H, values when CCR was above median value; L, values when CCR was below median value; n, number of
measurements; U Ox, urine oxalate (normal0.46 mmol/day); P Ox, plasma oxalate (normal1.8 uM/l); CCR, creatinine clearance per 1.73 m2; FL OX, filtered
oxalate; Ox Sec, absolute oxalate secretion; SSOX, calculated proximal tubule CaOx supersaturation. Missing SE indicate 3 measurements for that variable.
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units of PT and urine oxalate concentration will match; V is urine flow
rate, and g is GFR both in the same units.
Equation 2 reduces to Eq. 3 given that g  V 	 (Ucr/Pcr):
PTox Uox ⁄ U ⁄ Pcr 1 ⁄ 1 r (3)
Essentially Eq. 3 performs 2 separate transformations. Dividing urine
oxalate molarity by the urine to plasma creatinine concentration ratio
removed effects of all water extraction along the entire nephron. The
term [1/(1  r)] adds back effects of water removal along the PT.
Values for r, estimated in normal humans from lithium clearances,
range from 75 to 90% (2, 4, 19, 54). In patients with chronic kidney
disease (creatinine values 3.5 mg/dl), r averaged 75% (10, 44, 50).
Because loop and distal reabsorption of lithium cannot be ruled out or
quantified in humans, r may be less than these estimates. In animals,
micropuncture measurements of PT water reabsorption using tubule
fluid to plasma inulin ratios range from 44 to 67%, but these mea-
surements may not include all of the cortical convolution and neglect
reabsorption in the S3 segment (9, 31, 44). Given these observations
we have chosen 75% reabsorption, which creates a fourfold increase
in PT oxalate from water extraction: in other words 1/1  r  4.
If Uox is in M 	 106 and ultrafiltrate (UF) calcium (UFca) is
M 	 103, which are customary, the PT molar concentration product
is in M2 	 109. We (55) have found an average value of 40 	 109
M2 for this concentration product in human plasma ultrafiltrates
incubated at 37°C with CaOx seed crystals for an interval long enough
to achieve equilibrium. Therefore, PT SS, the ratio of the molar
product in PT to that at equilibrium, is calculated as:
PTss UFca PTox ⁄ 40 (4)
An SS value of 1 is by definition the empirical solubility since the
denominator was measured in ultrafiltrates in equilibrium with CaOx
crystals. Values 1 imply crystals will dissolve; values 1 indicate a
driving force for crystal formation.
Statistical Methods and Analysis
Means  SE were calculated for the key variables of interest:
plasma oxalate molarity, urine oxalate excretion, urine volume flow
rate, CCr, oxalate filtered load, and SS. Linear regression was used to
assess relationships among plasma oxalate and CCr, urine oxalate
excretion, and both filtered loads of oxalate and SS. Calculations were
performed using conventional software (Systat, Point Richmond, CA).
RESULTS
Patients
We obtained data from 11 patients; clinical data are shown for
all patients who had a surgery (Table 1). Three further PH1
patients who did not have surgery or ESRD contributed plasma
and urine oxalate measurements. The number and timing of
samples from each patient is shown in Table 2. Routine laboratory
values from all 11 patients documented hyperoxaluria (Table 3).
All cases were verified as PH1 by genetic analysis.
Three Hypothesis Tests
Plasma and urine oxalate, oxalate secretion, and PT CaOx
SS. Plasma oxalate concentration and creatinine clearance were
inversely associated (Fig. 1, top left). Urine oxalate excretion
increased in parallel with oxalate filtered load (Fig. 1, top right)
and most points lie above the diagonal line of identity indicating
oxalate secretion. The cluster of points from our prior studies (4)
of normal subjects and idiopathic calcium stone formers (Fig. 1,
top right, grey circles) does not depart from the line of identity
indicating that secretion is of minor overall quantitative signifi-
cance in these subjects. Absolute oxalate secretion rates for PH1
patients almost all exceeded zero (Fig. 1, bottom left). Values from
the ESRD cases obtained before the onset of dialysis (black
circles), and the three PH1 patients for whom we did not have
tissue (grey triangles), far exceeded values of the PNL cases
(black triangles). Posttransplant secretion values (grey diamonds)
were similar to those of PNL patients. Our prior study patients,
being normal subjects and idiopathic calcium stone formers,
showed the expected secretion values that varied from modestly
below to modestly above zero (grey circles).
Proximal tubule fluid CaOx SS (Fig. 1, bottom right) exceeded
1 (horizontal line) in a majority of the PH1 patients whereas
values in our prior normals and calcium stone formers were all
1, as were three of the posttransplant values and the PH1 patient
who was pyridoxine responsive (Table 3). PT SS and urine
oxalate excretion were directly correlated. It tended to fall after
transplant as urine oxalate fell. Overall, PT CaOx SS is plausible
in a majority of PH1 patients but not in normal subjects.
Evidence for PT CaOx crystals in otherwise normal renal
cortex of PH1 patients. The only cortical abnormality in our
PNL cases was the presence of tiny birefringent crystals on the
surfaces of a few PT cells identified via lectin staining as well
as morphology (Fig. 2, A and B). These birefringent crystals
were present in two PT of each patient. Being in outer cortex
these must be S1 or S2 PT. Mean predicted PT SS values for
the S3 segments of these two patients were about twofold
(Table 3, patients 6 and 7). In other words, we found crystals
in PT segments whose SS values would presumably be less
than those of the S3 segment; finding the crystals proves that
SS CaOx must exceed 1. The PT that had crystals at their brush
borders (Fig. 2B) were otherwise normal appearing: no inflam-
mation or fibrosis was found. Hyaluronan staining was nega-
tive (Fig. 2C). Masson trichrome staining showed no evidence
of cortical interstitial fibrosis (Fig. 2A, inset).
Evidence for preferential deposition of CaOx crystals in S3
segments. In kidneys harvested shortly after onset of dialysis
(Table 1, patients 1 and 5) tubule deposits concentrated at the
corticomedullary junction within PT lumens, cells, and the
surrounding interstitial space (Fig. 2, D and E). In other words,
the crystals concentrated in the S3 segments. By contrast, in
kidneys harvested after prolonged dialysis (Table 1, patients 2
and 4) widely scattered intraluminal deposits were found
throughout the entire cortex (not shown). Crystals were iden-
tified as CaOx by birefringence and FTIR.
All sites of intraluminal deposits, including both crystals and
lining cells across the entire cortex of patients 1, 2, 4, and 5,
stained with hyaluronan (Fig. 2F, arrow). Hyaluronan staining
also occurred in numerous normal appearing PT segments that
contained no crystals (Fig. 2F, arrowheads). In the early ESRD
cases, cortical and outer medullary collecting ducts contained
few crystals and were negative for hyaluronan whereas PT in
the same compartments contained masses of crystals (Fig. 2E)
and were hyaluronan positive.
Additional Observations
During the course of our hypothesis testing we necessarily
made additional observations that have not as yet been described:
papillary vs. cortical disease in PH1 patients with well- preserved
renal function studied via PNL biopsies, early vs. late ESRD
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tissue changes in both papilla and cortex, and surgical anatomy of
PH1 as viewed during intraoperative digital photography.
Relationship between papillary and cortical disease. PNL
PAPILLAE. As in most stone diseases, papillary injury far ex-
ceeded cortical injury. Scattered inner medullary collecting
ducts (IMCD) were plugged with CaOx crystals (Fig. 3A)
which were birefringent (Fig. 3A, top left inset). Extensive
interstitial fibrosis involved most of the papillary tip adjacent to
and distant from plugged ducts (Fig. 3, A–C, arrowheads).
Crystals were occasionally seen in IMCD cells but not the
interstitium (Fig. 3C, arrows). In both patients IMCD plugs and
cells were hyaluronan positive (Fig. 3D), as were some IMCD
with no plugs and otherwise normal histology.
ESRD papillae and cortex. Papillary changes in ESRD
kidneys (Fig. 4, A and B) are more severe than those of PNL cases,
and cortical disease is massive. The density of IMCD plugging as
seen on CT (Table 4 and Fig. 4, A and B) was far greater than
that observed in the PNL specimens (Fig. 3A, bottom right inset),
and hyaluronan staining matched areas of fibrosis (Fig. 4C). In the
cortex, tubular atrophy, interstitial fibrosis, and basement mem-
brane thickening are extreme in all nephrectomy specimens (Ta-
ble 4). Some regions (Fig. 4D) exhibit exotubulosis (55).
Endoscopic surgical anatomy. The papillary appearance of
PH1 is so particular as to suggest the diagnosis during surgery,
and we include it here as a clinical point that has not been
described before. Randall’s plaque was virtually absent in ESRD
and PNL kidneys. Three of the five visualized papillae of patient
3 were flattened and contained widely dilated Bellini ducts (BD)
and yellow suburothelial deposits (Fig. 5A) known to reflect
IMCD crystals (11, 12, 14, 17). The six visualized papillae of
patient 6 appeared normal except for scattered yellow deposits
(Fig. 5B). Patient 7 was studied twice. During the first procedure,
9 of 10 papillae were normal, 1 was flattened and had scattered
yellow deposits (Fig. 5C), and a few dilated BD had protruding
plugs. At the second procedure 2 yr later, a prior normal papillum
had an eroded tip and a protruding plug with an overgrowing
stone, meaning that damage had progressed (Fig. 5D). Ten
months after the second procedure (Table 1), this patient had
progressed to ESRD. The single papilla visualized in patient 11
was normal (not shown). Papillary abnormalities were much more
marked in the ESRD vs. the PNL cases (Fig. 5, E and F).
DISCUSSION
Tests of Our Hypothesis
Overview of the evidence supporting PT CaOx SS and PT
CaOx crystal formation. Our measurements of urine oxalate
along with calculations derived from mass balance indicate that
PT tubule fluid is likely to be supersaturated with respect to
CaOx in many patients with PH1. This calculation predicts that
CaOx crystals might be found in the PT of patients with normal
or near normal renal function, and we confirmed that predic-
tion. In two of two PH1 PNL cortical biopsies we found
birefringent crystals on the apical surfaces of PT cells that are
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Fig. 1. Oxalate physiology and tubule calcium
oxalate supersaturation. Plasma oxalate rises
progressively with falling creatinine clearance
(top left). Urine oxalate excretion rises with
oxalate filtered load; a majority of points from
primary hyperoxaluria type 1 (PH1) cases lie
above the diagonal line of identity indicating
that oxalate secretion is present (top right).
Absolute oxalate secretion (bottom left) is
minimal in ordinary stone formers (grey cir-
cles), but present to a varying extent in the
PH1 patients. Estimated maximal proximal
tubule CAOx supersaturation (see METHODS)
rises with urine oxalate excretion (bottom
right) and exceeds 1, the solubility limit, in a
majority of PH1 patients. Symbols: black cir-
cles, patients 1, 2, 4, and 5 before transplant;
black triangles, patients 3, 6, 7, and 11; grey
triangles, patients 8, 9, and 10; grey diamonds,
PH1 patients 1, 2, 4, and 5 posttransplant; grey
circles, idiopathic calcium stone formers and
normals.
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otherwise normal by appearance and by the absence of hyalu-
ronan staining. The S3 segment is predicted to have the highest
CaOx SS, and our studies of kidneys from patients who have
not been on dialysis for an extended period support this
prediction in showing that the corticomedullary PT are indeed
a favored site of CaOx crystal accumulation. These observa-
tions and calculations converge on the idea that in PH1 CaOx
SS in the S3 segment leads to CaOx crystallization. That we
found crystals in the S1 or S2 segments in the PNL cases
indicates that SS1 must occur in segments even proximal to
the S3 segment.
Uniqueness of the PT crystals. Such crystals have not been
found in PT from any other human kidney stone disease
phenotypes thus far and are therefore unlikely to be artifacts.
Using oil immersion optics with polarization we found no
crystals in either the cortex or the medulla from 30 idiopathic
CaOx stone formers (11). We have found a few nonbirefrin-
gent crystals in the distal nephron segments but no crystals in
the PT of patients with primary hyperparathyroidism (14) and
cystinuria (12). Likewise, in none of the cortical sections of
patients with brushite stones (17), small bowel disease (18),
ileostomy (13), renal tubular acidosis (15), and obesity bypass
(16) have we observed a single PT crystal. Put another way we
have never encountered PT crystals in any stone forming state
thus far apart from PH1. We emphasize this point so as to
highlight the significance of the few tiny crystals we found in
the PT of our two PNL patients.
Structure of the PT crystals. That the tiny crystals are CaOx
is inferred but unproven. Birefringence is not a property of
hydroxyapatite or brushite crystals. While monosodium urate
and cystine crystals are strongly birefringent under the appro-
priate fixation methods, it is most unlikely that monosodium
urate or cystine are forming in PT of PH1 patients (45).
Corticomedullary crystal accumulation. That the cortico-
medullary junction seems a preferred site for crystal formation,
specifically in the S3 PT segments, is not incompatible with
what is known about the physiology of this segment. The S3
segments lose water into the outer medullary interstitium that
is rendered hypertonic to blood via NaCl reabsorption in water
impermeable thick ascending limbs (25). Therefore, S3 seg-
ment tubule fluid would be predicted to have higher SS than the
cortical PT segments and be a preferred site for crystals.
Possibly, CaOx accumulation is also fostered by the abrupt
reduction of tubule diameter at the transition from S3 to the
thin descending limb of Henle’s loop (26). Our PNL biopsies
do not include S3 segments, so we cannot comment on crystal
A B
C D
E F
Fig. 2. Histopathologic images of cortical
biopsies from percutaneous nephrolithotomy
(PNL) and end stage renal disease (ESRD)
PH1 patients. Yasue-stained cortical biopsy
sections from PNL patients 7 (creatinine
clearance 123  16; A) and 6 (creatinine
clearance 74  6) (not shown) revealed nor-
mal glomerular (arrowhead) and proximal
tubule (arrows) morphology and no mineral
deposits. Only minimal interstitial fibrosis
was detected by Masson trichrome stain (A,
inset) in the cortical biopsies. However, oc-
casional small birefringent crystals (B, white
arrows) were noted at the brush border of
otherwise normal appearing proximal tubular
cells of both PNL patients. No hyaluronan
stained proximal tubular cells (arrows) or
glomeruli (arrowheads) were seen in the cor-
tical biopsies of patients 6 (C) and 7 (not
shown). Low magnification, light micros-
copy (D) shows widely scattered mineral
deposition concentrated within the lumens of
proximal tubular segments and the intersti-
tium at the corticomedullary junction (be-
tween arrowheads, dark black-brown mate-
rial) of ESRD patient 1. This crystalline
pattern of the ESRD patient is in stark con-
trast to the lack of large cortical deposits in
the PNL PH1 patients (A). E: Yasue-positive
deposits in the lumen of the S3 segment of
the proximal tubule shown here within the
outer stripe of the outer medulla. A nearby
outer medullary collecting duct is marked by
a white arrowhead. Hyaluronan staining of
cortical tissue from patient 1 (F) shows in-
traluminal deposits (arrow) along with the
apical cell surface of the adjacent proximal
tubular cells positive for hyaluronan as well
as positive staining of numerous nearby tu-
bular segments (arrowheads), primarily proxi-
mal tubules, that do not possess intraluminal
deposits. Original magnification: 	100 (A and
E); 	200 (B); 	50 (C); 	75 (D); 	125 (F).
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formation there. Our evidence for preferential S3 crystal accu-
mulation in ESRD kidneys seems convincing and is consistent
with the physiology of that segment.
Potential Limitations of Our SS Calculation
Lithium estimates of reabsorption. To convert our estimates
of PT fluid oxalate concentration into estimates of PT SS, we
have used conventional means. In humans, endogenous lithium
clearance is widely accepted as a marker for PT reabsorption,
and most measurements give an average value of 80–90% of
filtered fluid reabsorbed (6, 49). Possibly these high values
could reflect lithium reabsorption beyond the PT in the loops of
Henle or distal convolution (6, 49, 53, 57). To allow for this we
have assumed reabsorption of 75%; this would increase tubule
fluid oxalate concentration by fourfold (see METHODS). In es-
sence by dividing urine oxalate molarity by the urine to plasma
creatinine ratio (see METHODS, Eq. 4), we have removed all
effects of water extraction along the nephron and have added
back a fourfold concentration by water extraction in PT as
estimated from lithium clearance. An unstated assumption is
that all oxalate that enters PT, by filtration or net secretion, is
excreted in the urine.
Effects of reduced GFR on PT reabsorption. One might
guess that given chronic kidney disease PT fluid reabsorption
would fall, but in animal micropuncture experiments fractional
reabsorption of sodium and fluid is generally constant or falls
only to a slight extent (22, 42, 61). In studies of humans with
stages 2–4 nonnephrotic chronic kidney disease, lithium reab-
sorption has averaged 70–75%, close to our assumed value
(10, 48); this means our calculations may well be valid even in
PH1 patients who have lost significant renal function.
If a lower value for PT reabsorption is chosen, for example,
50%, the estimate for PT supersaturation would be about half
as high. However, this would not affect our finding of crystals
in PT on the biopsies of the patients who underwent biopsy at
a time when renal function was still near normal or only
modestly impaired. This would tend to strengthen the argument
that PT is particularly vulnerable to crystal formation, even at
relatively low levels of supersaturation, perhaps due to lack of
crystallization inhibitors at this site in the nephron.
SS calculations. Throughout its length, PT fluid calcium con-
centration appears to approximate that of ultrafiltrate or 1.1
mM/l (34). From this and estimated PT oxalate molarity we have
calculated the CaOx molar product and divided by the empirical
molar product in normal human plasma ultrafiltrate at equilibrium
with CaOx crystals to obtain a relative SS; this is standard practice
in kidney stone evaluation (19) and has been applied to estimate
serum SS from oxalate retention in chronic kidney disease and
dialysis (60). In perfused rabbit S3 segments Rouse et al. (41)
observed what appeared to be active calcium reabsorption, so
A
B
C
D
Fig. 3. Histopathologic changes of papillary
biopsies from PNL PH1 patients. Yasue (A
and C, arrows) and microcomputed tomog-
raphy (CT) images (A, bottom right inset)
of papillary biopsies of both patients 6 (cre-
atinine clearance 74  6) and 7 (creatinine
clearance 123  16) detected varying sized
intraluminal deposits in a few inner medul-
lary collecting ducts (IMCD). All deposits
are birefringent (A, top left inset) when
viewed by polarizing optics. Tissue sections
stained with Masson trichrome to mark sites
of fibrosis a greenish-blue revealed extensive
interstitial fibrosis at sites adjacent to and
away from (B, arrowheads) intraluminal de-
posits. Extensive interstitial fibrosis is also
seen the Yasue-stained sections (A and C) at
(arrows) and away from sites of deposits
(arrowheads). Prominent hyaluronan stain-
ing was noted in biopsies from the papillary
tip from both patients 6 and 7 (D, patient 6).
Two large intraluminal deposits (marked by
arrows) show hyaluronan staining of the
crystalline material as well as adjacent lining
cells. A number of nearby IMCD segments
with no intraluminal deposits also show hya-
luronan staining of their apical cell surface
(arrowheads). This staining pattern is in stark
contrast to the lack of hyaluronan staining in
the outer cortex of patients 6 and 7. Original
magnification: 	75 (A); 	100 (B and D);
	200 (C).
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possibly our assumption that PT calcium molarity equals that of
plasma ultrafiltrates overestimates SS to some extent.
Links Among Secretion, Plasma Oxalate, PT SS,
and Renal Function
Oxalate secretion. Proximal tubules are the known site of
oxalate secretion presumably via SLC26a6 and a1 transporters
(35, 46). Our measurements confirm oxalate secretion is the rule
in PH1, whereas in normal subjects and common stone formers it
is variable and of relatively trivial magnitude. Our PH1 patients
have plasma oxalate concentrations 3 to 40 times above normal,
which may be driving secretion but this cannot be rigorously
tested in our experiments. In a general linear model with oxalate
secretion as dependent and CCr, plasma oxalate, and urine oxalate
as independents, secretion had large and expected partial correla-
tions with CCr and urine oxalate excretion (0.62 and 0.71,
respectively, P  0.001 for both) but not a significant one with
plasma oxalate (0.051, P  0.7). Since secretion is calculated as
the difference between urine oxalate excretion and filtered oxalate
load (the product of plasma oxalate and CCr), one cannot proceed
further with stepwise regression because if either of the latter two
is entered as a variable the other becomes required in a tautolog-
ical fashion.
Effects of reduced GFR. Our calculation requires that CaOx
SS in PT rise hyperbolically as GFR falls (see METHODS). Since the
calculations are based on mass balance, and the obvious fact that
oxalate production and excretion do not fall with falling GFR, we
believe this is probably the fact and that, therefore, PT CaOx
crystal formation is not rare in ordinary forms of chronic renal
disease and certainly in the renal disease of PH1. This is beyond
A
B
C
D
Fig. 4. Histopathologic changes in cortical
and papillary biopsies from ESRD PH1 pa-
tients. A: CT image of a kidney from pa-
tient 1 that shows the pattern of crystalline
deposits from the renal capsule to the papil-
lary tip. While a few mineral deposits are
present in the outer cortex (also see Fig. 2D),
the majority of crystals are concentrated at
the corticomedullary junction (between ar-
rowheads) with extensive mineral deposition
in the papillary tips (double white arrows)
and stones in minor calyces (single white
arrows). Light microscopy (B) shows large
dilated IMCD filled with mineral (double
arrows) and when examined by polarizing
optics (top left inset) contains only birefrin-
gent material. Stone material (single arrow)
was noted in the minor calyx. This pattern of
mineral deposition is identical to that seen by
CT (Fig. 4A). The same pattern of hyalu-
ronan staining seen in the cortex of patient 1
(Fig. 2F) is noted in the inner medulla (C),
hyaluronan positive intraluminal deposits
(arrow) as well as staining of nearby nephron
segments, in this case IMCDs (arrowheads)
that do not possess intraluminal deposits.
High magnification light microscopic images
of the cortex shows crystalline deposits in
the lumens (arrows) and cells (arrowheads)
of primarily proximal tubules (D) as well as
the interstitium (double arrows). Sites of
exotubulosis (arrowheads) are noted in some
proximal tubules. Extensive interstitial fibro-
sis encapsulates many cortical nephron seg-
ments (D). Original magnification: 	5 (A);
	50 (B); 	100 (C); 	125 (D).
Table 4. Tissue, crystals, and pathology
Patient
Papillary Deposits
Cortical Pathology Score
#Glomeruli
Glomerular pathology
Tubular atrophy Interstitial fibrosisAverage size, mm #/mm3 Mild Moderate Global
1 1.9 27 11 1 7 3 3 3
2 1.2 27 19 1 2 16 3 3
4 1.8 25 22 0 0 22 3 3
5 1.5 29 18 1 17 0 3 3
6 0.3 2.4 5 5 0 0 1 1
7 0.6 3 2 2 0 0 1 1
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the scope of the present work but suggests that search for such
crystals in renal biopsies might be productive.
Crystal Clearance Mechanisms and Crystal-Mediated Injury
in PH1
Possible balance between crystal formation and clearance.
The fact that PT SS seems common and persistent and that tiny
crystals can be found in the absence of cell damage in PT
suggests that some mechanisms must exist to clear crystals
from the tubules so crystals do not accumulate. Indeed, PT
cells can clear crystals via exotubulosis (55). We found this
process in our ESRD kidneys and presume it can occur earlier
in the disease. As well, some crystals can be taken up by PT
cells, as we found in our ESRD samples, and digested in their
lysosomes (34). The tiny crystals found in our PNL patients do
not appear to have triggered inflammation, based on the ab-
sence of staining for hyaluronan (2, 55, 56). One might spec-
ulate that given SS as a driver of crystallization, and these cell
processes, one can envision a kind of stable equilibrium be-
tween formation and removal that can be disturbed by in-
A B
C D
E F
Fig. 5. Intraoperative and ex vivo endoscopic
images of papillae from PNL (cases 3, 6, and
7) and ESRD (cases 1 and 2) PH1 patients.
A–D: intraoperative endoscopic images col-
lected at the time of mapping and stone
removal from patients 3 (A), 6 (B), and 7 (C
and D). Papillary morphology varied from
normal (B and C) to flattened (A and D). A
few dilated ducts of Bellini (A and C, *) with
(C, double arrows) and without (A, *) pro-
truding plugs were seen scattered between
sites of yellow plaque (arrowheads). The
same kidney of patient 7 seen in C was
studied a second time 2 yr later and one
papilla now showed an eroded tip and a
protruding plug with a stone overgrowth not
seen previously (D, arrow). With the use of
ex vivo ureteroscopy, nonadherent stones (E,
arrow) were noted lying on a papillary tip in
patient 1, an adult with PH1 and ESRD.
Removal of one of these stones revealed a
dilated opening to a duct of Bellini (E, *).
Small sites of yellow plaque (arrowheads)
are noted nearby. F: ex vivo ureteroscopy
image from patient 2, an infant with PH1 and
ESRD. A dilated opening to a duct of Bellini
(*) and sites of yellow plaque (arrowheads)
appear similar to that seen in patient 1 in E,
however, no stones are found.
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creases of PT fluid reabsorption, acute or chronic reductions of
GFR both of which will increase PT CaOx SS, or a disturbance
of clearance mechanisms.
Cortical injury. The links between CaOx crystals and PT
cell damage have been described by others (8, 21, 27–31, 43,
52) and are beyond the scope of this report. Recently, two
groups have reported that renal inflammation and tissue injury
in rodent models of acute oxalate toxicity are mediated by
NLRP3. The site of greatest injury in their studies was at the
inner stripe of the outer medulla, as seen in the patients who
had early ESRD (33, 38). Whether the tissue injury in PH1 is
induced by the same mechanisms is unclear. Our work dem-
onstrates that in patients with preserved renal function crystals
form in PT without inducing tissue injury or inflammation
demonstrable with standard histologic methods; what trans-
forms this noninjurious crystal formation into the injury pattern
seen in patients with early ESRD remains to be discovered.
Quite possibly those patients with the highest PT SS may form
the most PT crystals, trigger an inflammatory process leading
to injury, and progress most rapidly to ESRD; this can be tested
by prospective observational studies. Likewise episodic reduc-
tions in GFR may cause acute renal injury with rapid crystal
deposition that eventuates in ESRD.
Papillary injury. Our PNL biopsies show that papillary
injury far exceeds cortical injury in PH1 as it can in all kidney
stone-forming phenotypes we have studied to date (12–18). We
presume this disproportion of damage between papilla and
cortex reflects the corresponding disproportion of CaOx SS and
crystallization potential. Whereas cortical SS is predicted to be
two- threefold (Table 3), urine SS for CaOx is always much
higher (40). In idiopathic CaOx stone formers cortical SS is
null, as shown in Fig. 1, and cortical tissue normal (not shown).
In PH1 crystal deposition, although marked, is not greater than
in such states such as renal tubular acidosis, but the amount of
fibrosis is much greater. The mechanisms for this disproportion
is presently unknown.
Clinical Implications
Possible importance of maintaining a high sodium intake.
Factors that reduce GFR and/or increase PT reabsorption, such
as extracellular volume depletion may well be dangerous in
PH1. All stone patients have increased stone risks from dehy-
dration (7); in PH1 not only papillary stones but PT crystals
may be fostered. Water alone would not be predicted to have
any effect on PT reabsorption since it would act by lowering
vasopressin, which acts at later sites in the nephron; only high
sodium intake can reduce PT reabsorption (47). Therefore, a
high-salt diet might be of benefit, and sodium depletion from
diet or diuretics might be harmful in PH1. Clinical trials would
be needed to test these conjectures.
Surgical diagnosis. The unique surgical appearance of PH1
can alert clinicians to the diagnosis. Stones do not form on
interstitial (Randall’s) plaque but are either free in the collect-
ing system or growing on plugs. IMCD plugging is common in
calcium phosphate stone formers (15, 17), and those with
hyperparathyroidism (14) and bowel diseases (13, 18), but PH1
patients form CaOx stones, and systemic diseases can be
excluded clinically. In other words, a CaOx stone former with
tubule plugging, minimal or no interstitial plaque, and no ap-
parent systemic or bowel disease should raise suspicion of PH1
and be studied appropriately.
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